Surrozen (SRZN) Stock Price, News & Analysis

Company Overview

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Key Stats

• Today's Range: $11.76 to $12.94
• 50-Day Range: $8.44 to $17.02
• 52-Week Range: $6.00 to $18.17
• Volume: 32,334 shs
• Average Volume: 47,412 shs
• Market Capitalization: $39.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.00
• Consensus Rating: Buy

Surrozen Stock Analysis - MarketRank™

Surrozen scored higher than 64% of companies evaluated by MarketBeat, and ranked 425th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Surrozen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Surrozen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Surrozen has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.94% of the float of Surrozen has been sold short.

Short Interest Ratio / Days to Cover

Surrozen has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Surrozen has recently increased by 2.20%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Surrozen does not currently pay a dividend.

Dividend Growth

Surrozen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.94% of the float of Surrozen has been sold short.

Short Interest Ratio / Days to Cover

Surrozen has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Surrozen has recently increased by 2.20%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Surrozen this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for SRZN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Surrozen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Surrozen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,157.00 in company stock.

Percentage Held by Insiders

43.50% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SRZN Stock Analysis - Frequently Asked Questions

How have SRZN shares performed this year?

Surrozen's stock was trading at $14.35 at the beginning of 2025. Since then, SRZN stock has decreased by 15.8% and is now trading at $12.08.
View the best growth stocks for 2025 here.

How were Surrozen's earnings last quarter?

Surrozen, Inc. (NASDAQ:SRZN) released its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($2.77) by $2.33. The firm earned $10 million during the quarter.

When did Surrozen's stock split?

Surrozen's stock reverse split on the morning of Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Surrozen?

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Surrozen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Surrozen investors own include ACADIA Pharmaceuticals (ACAD), Marvell Technology (MRVL), HubSpot (HUBS), Avidity Biosciences (RNA), Adverum Biotechnologies (ADVM), Alpha and Omega Semiconductor (AOSL) and

Company Calendar

• Last Earnings: 11/06/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 4/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SRZN
• CUSIP: N/A
• CIK: 1824893
• Web: www.consonancehfw.com
• Phone: 650-489-9000
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $45.00
• High Stock Price Target: $45.00
• Low Stock Price Target: $45.00
• Potential Upside/Downside: +272.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-43,040,000.00
• Net Margins: N/A
• Pretax Margin: -444.38%
• Return on Equity: -120.51%
• Return on Assets: -54.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.40
• Quick Ratio: 7.40

Sales & Book Value

• Annual Sales: $12.50 million
• Price / Sales: 3.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.39 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 3,250,000
• Free Float: 1,836,000
• Market Cap: $39.26 million
• Optionable: Not Optionable
• Beta: 0.77